- Home
- VRNT vs SNDX Comparison
VRNT vs SNDX Comparison
Compare VRNT & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNT
- SNDX
- Stock Information
- Founded
- VRNT 1994
- SNDX 2005
- Country
- VRNT United States
- SNDX United States
- Employees
- VRNT N/A
- SNDX N/A
- Industry
- VRNT EDP Services
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- VRNT Technology
- SNDX Health Care
- Exchange
- VRNT Nasdaq
- SNDX Nasdaq
- Market Cap
- VRNT 1.5B
- SNDX 1.2B
- IPO Year
- VRNT N/A
- SNDX 2016
- Fundamental
- Price
- VRNT $24.29
- SNDX $16.38
- Analyst Decision
- VRNT Buy
- SNDX Strong Buy
- Analyst Count
- VRNT 7
- SNDX 10
- Target Price
- VRNT $35.67
- SNDX $36.20
- AVG Volume (30 Days)
- VRNT 442.7K
- SNDX 2.5M
- Earning Date
- VRNT 03-26-2025
- SNDX 03-04-2025
- Dividend Yield
- VRNT N/A
- SNDX N/A
- EPS Growth
- VRNT 2980.37
- SNDX N/A
- EPS
- VRNT 0.95
- SNDX N/A
- Revenue
- VRNT $920,749,000.00
- SNDX $16,000,000.00
- Revenue This Year
- VRNT $4.50
- SNDX N/A
- Revenue Next Year
- VRNT $4.50
- SNDX N/A
- P/E Ratio
- VRNT $25.33
- SNDX N/A
- Revenue Growth
- VRNT 4.45
- SNDX N/A
- 52 Week Low
- VRNT $21.28
- SNDX $12.06
- 52 Week High
- VRNT $38.17
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- VRNT 37.65
- SNDX 68.27
- Support Level
- VRNT $25.48
- SNDX $14.53
- Resistance Level
- VRNT $26.62
- SNDX $15.40
- Average True Range (ATR)
- VRNT 0.87
- SNDX 0.70
- MACD
- VRNT -0.08
- SNDX 0.13
- Stochastic Oscillator
- VRNT 12.46
- SNDX 82.93
About VRNT Verint Systems Inc.
Verint Systems Inc with its subsidiaries helps brands provide Boundless Customer Engagement. The company's solutions help iconic brands close the gap created when it lacks the resources required to deliver experiences that fulfill customer expectations. Geographically, it derives a majority of its revenue from the United States.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.